LL-37 Peptide Research

Interest in LL-37 peptide research has increased across microbiology, immunology, wound healing and regenerative medicine. Common searches now include LL-37 results, LL-37 UK, LL-37 antimicrobial peptide, UK peptides and peptides UK.

LL-37 is often described online as a natural antibiotic or immune-support peptide. Although it does possess direct antimicrobial properties, this description is incomplete. LL-37 is a multifunctional human defence peptide that can influence microbial membranes, immune-cell recruitment, inflammation, blood-vessel formation and tissue repair.

Its activity is also highly dependent on biological context. LL-37 can reduce inflammatory responses under some experimental conditions while amplifying them in others. It has been associated with wound repair and antimicrobial defence, but excessive or misplaced LL-37 signalling also contributes to inflammatory skin disorders such as psoriasis and rosacea.

At Elvian Labs, we believe it is important to distinguish this complex endogenous biology from claims made about externally administered research-grade LL-37. This article reviews what LL-37 is, how it works and what laboratory, animal and early human research currently shows.

What Is LL-37?

LL-37 is a naturally occurring human peptide composed of 37 amino acids.

It is the best-known active fragment of human cathelicidin antimicrobial protein, usually called hCAP18. The full precursor protein is produced by several cell types and can be enzymatically processed to release LL-37.

The name refers to the first two amino acids—leucine and leucine—followed by its total length of 37 amino acids.

LL-37 is found in tissues and biological fluids including:

• Skin
• Respiratory secretions
• Saliva
• Wound fluid
• The gastrointestinal tract
• Reproductive tissues
• Immune cells
• Bone marrow

Neutrophils contain substantial amounts of hCAP18 within specialised granules and can release it during infection or tissue injury. Epithelial cells, macrophages, keratinocytes and other cell populations can also produce cathelicidin in response to infection, injury and inflammatory signalling.

LL-37 is currently regarded as both an antimicrobial peptide and a broader host-defence peptide because many of its effects involve modifying the host response rather than directly killing microorganisms. (PubMed)

How Is LL-37 Produced?

LL-37 is not generally manufactured inside cells as an isolated 37-amino-acid peptide.

Instead, the human CAMP gene encodes the precursor protein hCAP18. Enzymes then cleave the C-terminal portion of that protein to release LL-37 or related fragments.

This processing system allows the body to store a less active precursor and generate biologically active peptides when required.

Expression of the CAMP gene is influenced by several signals, including active vitamin D. Laboratory research has shown that the vitamin D receptor can increase cathelicidin expression in human cells, linking vitamin D signalling with aspects of innate antimicrobial defence. (PubMed)

This does not mean that increasing vitamin D will necessarily produce unlimited LL-37 or provide protection against every infection. Cathelicidin regulation also depends on tissue type, immune activation, genetics and local enzymatic processing.

LL-37 Structure and Membrane Activity

LL-37 is positively charged and can form an amphipathic alpha-helical structure under suitable conditions.

An amphipathic structure contains regions attracted to water and regions attracted to lipids. This allows LL-37 to interact with microbial cell membranes, which are often more negatively charged than human cell membranes.

After binding, LL-37 may disrupt membrane organisation, increase permeability and contribute to the loss of essential cellular contents.

Structural research has shown that the peptide associates with negatively charged membrane-like surfaces through much of its helical sequence. Scientists have also identified shorter fragments, including KR-12, that retain selected antibacterial properties. (PubMed)

The precise mechanism varies between organisms and may include:

• Membrane thinning
• Transient pore formation
• Surface disruption
• Membrane fragmentation
• Entry into the microbial cell
• Interaction with internal microbial targets

LL-37 should therefore not be understood as acting through one single antibiotic-style receptor.

Antibacterial Research

In laboratory conditions, LL-37 has demonstrated activity against a range of Gram-positive and Gram-negative bacteria.

The peptide has been studied against organisms including:

• Escherichia coli
• Pseudomonas aeruginosa
• Staphylococcus aureus
• Salmonella species
• Klebsiella species
• Streptococcus species

However, antimicrobial potency measured in a simplified laboratory solution does not always persist in the human body.

Salts, serum proteins, mucus, enzymes and components of wound fluid can bind to LL-37 or reduce its ability to interact with bacterial membranes. Some bacteria can also modify their surfaces, release proteases or form biofilms that reduce susceptibility.

This is one reason why promising antimicrobial activity in vitro has not yet translated into a broadly approved systemic LL-37 antibiotic.

LL-37 and Antibiotic Resistance

Antimicrobial peptides are of considerable scientific interest because their membrane-directed activity differs from that of many conventional antibiotics.

In theory, widespread membrane disruption may be harder for bacteria to escape through one simple genetic mutation. This has encouraged investigation of LL-37 fragments and engineered analogues as possible templates for future antimicrobial medicines.

However, bacteria can develop or possess resistance mechanisms against host-defence peptides. These include:

• Altering membrane charge
• Producing peptide-degrading enzymes
• Increasing capsule formation
• Activating efflux or stress-response systems
• Trapping peptides within biofilms
• Releasing molecules that neutralise positive charge

LL-37 is therefore not immune to microbial resistance, and its natural origin does not guarantee that it will remain effective against resistant pathogens.

Antiviral Research

LL-37 has also been investigated against several enveloped and non-enveloped viruses.

Proposed antiviral mechanisms include:

• Disruption of viral envelopes
• Binding directly to viral particles
• Interference with attachment to host cells
• Modulation of antiviral immune signalling
• Alteration of nucleic-acid recognition

The effect differs substantially between viruses, experimental conditions and peptide concentrations.

Some antiviral findings involve direct exposure of virus particles to LL-37 before infection. This is very different from administering the peptide to a living organism after a viral infection has already become established.

There is currently no strong clinical evidence that generic LL-37 is an effective systemic antiviral treatment in humans.

Antifungal and Biofilm Research

LL-37 has demonstrated experimental activity against selected fungi and has also been studied in bacterial and mixed-species biofilms.

Biofilms are structured communities of microorganisms surrounded by a protective extracellular matrix. They can form on wounds, medical devices, teeth and other surfaces, making infection more difficult to eliminate.

LL-37 may interfere with microbial attachment or biofilm development under some laboratory conditions. However, mature biofilms can also bind, degrade or neutralise antimicrobial peptides.

The concentrations required to disrupt an established biofilm may also approach levels that damage human cells, creating an important therapeutic limitation.

LL-37 Is More Than an Antimicrobial Peptide

One of the most important developments in LL-37 research was the recognition that its biological effects extend far beyond microbial killing.

LL-37 can interact with mammalian cell membranes and influence several signalling systems. Proposed molecular partners include:

• Formyl peptide receptor 2
• P2X7 receptors
• Toll-like receptors
• Epidermal growth factor receptor pathways
• Nucleic-acid sensing systems
• Membrane lipids
• Proteoglycans

Depending on the tissue and experimental model, LL-37 can affect:

• Chemotaxis
• Cytokine release
• Immune-cell activation
• Cell proliferation
• Angiogenesis
• Epithelial migration
• Apoptosis
• Tissue remodelling

This multifunctional biology explains both its regenerative potential and its capacity to aggravate inflammatory disease.

LL-37 and Immune-Cell Recruitment

LL-37 can act as a signalling molecule that attracts selected immune cells towards an area of infection or tissue injury.

This process, known as chemotaxis, may help recruit:

• Neutrophils
• Monocytes
• T cells
• Mast cells
• Dendritic-cell precursors

Recruitment of immune cells can improve early defence against microorganisms. However, excessive recruitment may also intensify inflammation and tissue damage.

The biological outcome therefore depends on whether LL-37 signalling is proportionate and appropriately localised.

Binding to Bacterial Toxins

LL-37 can bind lipopolysaccharide, or LPS, a component of the outer membrane of Gram-negative bacteria.

This interaction may reduce the ability of LPS to activate inflammatory signalling under certain laboratory conditions. It has contributed to interest in LL-37 and related peptides as possible approaches to bacterial inflammation or sepsis.

However, the native peptide can also be cytotoxic at higher concentrations, limiting its direct therapeutic use. Researchers have therefore investigated shorter fragments and altered analogues intended to preserve LPS-neutralising or antimicrobial activity while reducing toxicity. (PubMed)

No LL-37-based treatment has been established as a routine therapy for human sepsis.

LL-37 and Nucleic-Acid Sensing

LL-37 can bind DNA and RNA.

Normally, extracellular genetic material may be degraded or may enter immune cells inefficiently. LL-37 can form complexes with nucleic acids and help transport them into immune cells, where they activate intracellular pattern-recognition receptors.

Research has shown that LL-37 can greatly increase the detection of CpG-containing DNA by human B cells and plasmacytoid dendritic cells. (PubMed)

This mechanism may be useful during infection because it helps the immune system detect microbial genetic material. However, LL-37 can also bind human DNA released from damaged cells.

When self-DNA is delivered into immune-sensing pathways, it may generate inappropriate inflammatory or autoimmune responses.

LL-37 and Psoriasis

The interaction between LL-37 and self-DNA has become particularly important in psoriasis research.

In psoriatic skin, damaged cells release DNA and other cellular material. LL-37 can bind this DNA and form complexes that activate plasmacytoid dendritic cells.

These cells then produce type I interferons, helping initiate and sustain the inflammatory network involving dendritic cells, T cells and cytokines such as IL-23 and IL-17.

Rather than being deficient in psoriasis, LL-37 is often excessively expressed or biologically misplaced. Its normal host-defence function becomes part of a self-amplifying inflammatory process. (PubMed)

This is a clear example of why LL-37 should not simply be described as an anti-inflammatory peptide.

LL-37 and Rosacea

Abnormal cathelicidin processing has also been implicated in rosacea.

People with rosacea may produce increased amounts of cathelicidin and altered peptide fragments within the skin. These peptides can promote inflammation, blood-vessel changes and mast-cell activation.

Recent laboratory and animal research suggests that LL-37 can induce mitochondrial stress in mast cells, release mitochondrial DNA and activate the cGAS–STING inflammatory pathway. Blocking elements of this pathway reduced rosacea-like inflammation in experimental models. (PubMed)

The role of LL-37 in rosacea again shows that more antimicrobial peptide activity is not always beneficial.

Pro-Inflammatory and Anti-Inflammatory Effects

LL-37 is sometimes described as anti-inflammatory because it can neutralise bacterial LPS and reduce selected inflammatory cytokines.

Under other circumstances, it can increase inflammation by:

• Transporting DNA or RNA into immune cells
• Activating mast cells
• Increasing chemotaxis
• Enhancing damage-associated molecular signalling
• Promoting inflammasome-related pathways
• Increasing cytokine or prostaglandin production

Human-cell research has found that LL-37 can amplify inflammatory responses produced by damage-associated molecular patterns. (PubMed)

Its effect depends on factors including:

• Concentration
• Cell type
• Presence of infection
• Presence of damaged-cell material
• Receptor expression
• Timing
• Local tissue environment

The most accurate description is that LL-37 is immunomodulatory, with the potential to either restrain or intensify inflammation.

Wound-Healing Research

LL-37 is naturally present in wound fluid and has been studied extensively in skin-repair models.

Potential wound-related effects include:

• Keratinocyte migration
• Epithelial-cell proliferation
• Angiogenesis
• Recruitment of repair cells
• Antimicrobial defence
• Regulation of inflammatory signalling

Keratinocytes must move across the wound surface to restore the skin barrier. Laboratory research indicates that LL-37 can stimulate this migration and influence growth-factor signalling.

It has also been associated with blood-vessel formation, which may help provide oxygen and nutrients to repairing tissue.

These mechanisms provide a credible rationale for topical wound-healing research, although they do not establish that systemic LL-37 accelerates recovery throughout the body.

Animal Wound Models

Animal research has examined LL-37 in infected burns, chronic wounds and other forms of skin injury.

In one experimental infected-burn model, researchers used transient gene transfer to increase local hCAP18/LL-37 expression in the skin. This was investigated as a method of improving antimicrobial defence directly within the wound. (PubMed)

Other studies have tested peptide-loaded dressings, hydrogels and nanoparticle systems.

Delivery technology is particularly important because free LL-37 can be rapidly degraded by proteases within chronic wounds. It may also bind to biological material before reaching its intended target.

Human Diabetic-Foot-Ulcer Research

Some early human research has investigated topical LL-37 in diabetic foot ulcers.

A clinical study involving mildly infected diabetic foot wounds compared LL-37 cream with placebo over four weeks. The researchers evaluated wound-healing rate, inflammatory markers and bacterial colonisation. The study reported encouraging findings, but it was relatively limited and does not establish LL-37 as a standard treatment for diabetic foot ulcers. (PubMed)

Diabetic wounds are complex and can involve impaired circulation, neuropathy, infection and altered immune function. Findings from one topical formulation should not be generalised to injectable LL-37 or to other types of injury.

LL-37 and Angiogenesis

LL-37 can stimulate endothelial-cell activity and new blood-vessel formation in some experimental models.

Angiogenesis can be helpful during wound repair because newly forming tissue requires a blood supply.

However, blood-vessel growth is also involved in:

• Tumour progression
• Psoriasis
• Retinal disease
• Chronic inflammation
• Abnormal tissue remodelling

A peptide with pro-angiogenic activity cannot therefore be described as universally regenerative or protective.

Its biological desirability depends on where, when and why the new vessels are forming.

LL-37 and Cancer

The relationship between LL-37 and cancer is complex and varies between tumour types.

In some experimental systems, LL-37 or selected fragments have demonstrated direct toxicity against cancer cells. The membranes of some tumour cells have features that may make them susceptible to positively charged antimicrobial peptides.

In other models, LL-37 has been associated with:

• Increased tumour-cell proliferation
• Enhanced migration and invasion
• Angiogenesis
• Activation of growth pathways
• Recruitment of tumour-supporting immune cells

Research in skin squamous-cell carcinoma found that LL-37 promoted tumour-cell proliferation and invasion through pathways involving NF-κB and related signalling. (PubMed)

In ovarian-cancer models, tumour-derived signals increased LL-37 production by macrophages, which then supported tumour progression in cell-culture experiments. (PubMed)

Conversely, newer research continues to identify tumour models in which LL-37 appears inhibitory. This means LL-37 should not be labelled simply as either anticancer or cancer-promoting.

The outcome depends on:

• Tumour type
• Peptide concentration
• Local immune environment
• Receptor expression
• Delivery method
• Angiogenic signalling
• Whether full-length LL-37 or a fragment is studied

LL-37 and the Respiratory System

The respiratory epithelium produces cathelicidin as part of its innate defence system.

LL-37 is present in airway secretions and has been investigated in relation to bacterial pneumonia, viral infections, cystic fibrosis and chronic airway inflammation.

Within the lungs, its antimicrobial function can be reduced by salts, mucus and extracellular DNA. High concentrations can also damage epithelial cells or increase inflammation.

This may help explain why abnormal LL-37 levels have been associated with both protection from infection and inflammatory lung pathology in different settings.

Gastrointestinal Research

LL-37 is expressed within the gastrointestinal tract and may contribute to defence against invading microorganisms.

Research has explored its effects on:

• Intestinal bacteria
• Mucosal immunity
• Epithelial repair
• Inflammatory signalling
• Gut-barrier integrity

As with the skin and lungs, intestinal LL-37 activity must remain carefully regulated. Excessive inflammatory activation or membrane disruption could potentially injure host tissue.

Claims that LL-37 universally heals the gut are therefore not supported by current human evidence.

Bone and Dental Research

LL-37 has also been studied in bone-forming cells and periodontal tissues.

Laboratory research suggests that it may influence osteogenic differentiation, inflammatory signalling and repair responses in bone-marrow-derived stem cells. In one model, LL-37 reduced LPS-induced inflammatory markers while promoting osteogenic activity through pathways involving the P2X7 receptor. (PubMed)

Human periodontal-cell studies have also explored how LL-37 is internalised and modifies responses to bacterial inflammatory signals. (PubMed)

These are early mechanistic findings. They do not establish LL-37 as a proven treatment for bone injuries, dental infections or periodontal disease.

Why Is LL-37 Difficult to Develop as a Medicine?

Despite promising laboratory findings, native LL-37 has several limitations:

• Rapid enzymatic degradation
• Relatively short biological persistence
• Reduced antimicrobial activity in physiological salt conditions
• Binding to serum proteins and wound components
• Cytotoxicity at higher concentrations
• Potential inflammatory activation
• Lack of tissue selectivity
• Possible pro-angiogenic or tumour-supporting activity

Researchers are therefore investigating shorter fragments, modified analogues and delivery systems that might retain selected benefits while reducing unwanted effects.

Examples include:

• Hydrogels
• Nanoparticles
• Lipid carriers
• Peptide-coated wound dressings
• Protease-resistant analogues
• Shorter antimicrobial fragments

Recent nanocarrier research continues to focus on protecting LL-37 from degradation while limiting concentration-dependent cytotoxicity. (PubMed)

Full-Length LL-37 Versus Shorter Fragments

Not every peptide derived from LL-37 behaves identically to the full molecule.

Short fragments may retain antimicrobial activity while losing some immune, angiogenic or cytotoxic effects. KR-12, for example, was identified as a smaller region with antibacterial activity and greater selectivity for bacterial cells in the experimental system studied. (PubMed)

Other fragments may have different receptor interactions, membrane affinity or stability.

Research involving one LL-37-derived sequence should not automatically be attributed to:

• Full-length LL-37
• A different fragment
• A modified analogue
• A generic product labelled LL-37

Exact sequence identity is therefore essential when assessing the literature.

Injectable LL-37 Research

Most published LL-37 research involves cell cultures, animal models, local wound delivery or specialised formulations.

There is very little robust clinical evidence supporting systemic injectable LL-37 for infection, immune support, tissue healing or chronic inflammatory illness.

Systemic delivery could theoretically expose many tissues to its vasculogenic, inflammatory and membrane-active effects. Findings from topical wound studies should therefore not be used to establish the safety or effectiveness of intermittent subcutaneous administration.

There is no clinically validated universal injection protocol for LL-37.

Understanding “LL-37 Results”

Searches for LL-37 results, LL-37 experience or LL-37 before and after may produce anecdotal reports involving:

• Reduced infection symptoms
• Faster wound healing
• Changes in gut symptoms
• Temporary inflammation
• Skin reactions
• Fatigue or flu-like effects
• Changes in chronic inflammatory symptoms

Such reports cannot establish causation.

Possible confounding factors include:

• Natural resolution of infection
• Antibiotic or antifungal treatment
• Changes in wound care
• Concurrent peptide use
• Immune fluctuations
• Placebo effects
• Product degradation
• Incorrect peptide identity
• Endotoxin or microbial contamination

Anecdotal results also cannot reliably reveal whether immune activation that feels noticeable is beneficial or harmful.

Is LL-37 an Approved Medicine?

LL-37 is not broadly approved as a systemic treatment for infection, wound healing, autoimmune disease or immune support.

Topical formulations and LL-37-based delivery systems have entered early clinical or translational research, but these remain formulation-specific and indication-specific.

The existence of human wound research does not mean that generic LL-37 is an authorised medicine.

Research-Grade LL-37 and Pharmaceutical Evidence

Research-grade peptide material may differ substantially from the formulation used in a controlled experiment.

Important variables include:

• Amino-acid sequence
• Peptide purity
• Peptide content by mass
• Counter-ion content
• Water content
• Aggregation
• Sterility
• Endotoxin levels
• Proteolytic degradation
• Storage temperature
• Reconstitution stability

These factors are particularly relevant for LL-37 because contamination with bacterial endotoxin could itself produce inflammatory effects and confuse experimental findings.

Scientific evidence applies to the exact compound, formulation and delivery system that were studied.

LL-37 UK and Research Classification

Searches for LL-37 UK, UK peptides and peptides UK commonly lead to research-grade preparations supplied outside the conventional pharmaceutical system.

LL-37 is naturally present in the human body, but this does not mean that externally administered synthetic LL-37 is automatically safe.

Endogenous LL-37 is normally produced locally, processed enzymatically and regulated according to tissue conditions. External administration may create concentrations, exposure patterns and tissue distribution that do not occur naturally.

A research-labelled product should not be represented as an approved antibiotic, wound-healing treatment or immune therapy.

Current State of the Evidence

Among compounds discussed within the UK peptides research community, LL-37 has one of the most biologically complex profiles.

Laboratory research clearly demonstrates that LL-37 can disrupt microbial membranes, bind bacterial products and influence immune-cell signalling. It can recruit immune cells, transport nucleic acids into intracellular sensing pathways and affect epithelial migration, angiogenesis and wound repair. (PubMed)

Animal and early topical human research provide a rationale for further investigation in infected and chronic wounds. However, native LL-37 is limited by rapid degradation, concentration-dependent cytotoxicity and inconsistent activity within physiological environments. (PubMed)

Crucially, LL-37 is not universally anti-inflammatory. Excessive or abnormal signalling is implicated in psoriasis and rosacea, while its effects in cancer vary between tumour-suppressing and tumour-supporting activity depending on the model. (PubMed)

The most accurate interpretation of current LL-37 peptide research is that it is an important endogenous host-defence peptide with credible antimicrobial, immunological and wound-related activity.

It should not be portrayed as a natural replacement for antibiotics, a universal immune booster or a clinically proven systemic healing peptide.

This article is intended for educational purposes only and summarises published scientific research. It should not be interpreted as medical advice, a recommendation for human use or evidence of clinical efficacy for any unapproved application.